Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) — Market Cap & Net Worth
Market Cap & Net Worth: Ind-Swift Laboratories Limited (INDSWFTLAB)
Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) has a market capitalization of $152.59 Million (Rs14.11 Billion) as of June 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #17690 globally and #923 in its home market, demonstrating a 0.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ind-Swift Laboratories Limited's stock price Rs162.48 by its total outstanding shares 86836558 (86.84 Million). Review Ind-Swift Laboratories Limited balance sheet liabilities to assess the company's total debt and financial obligations.
Ind-Swift Laboratories Limited Market Cap History: 2015 to 2026
Ind-Swift Laboratories Limited's market capitalization history from 2015 to 2026. Data shows growth from $34.84 Million to $152.59 Million (15.32% CAGR).
Ind-Swift Laboratories Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ind-Swift Laboratories Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Ind-Swift Laboratories Limited's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.03x
Ind-Swift Laboratories Limited's market cap is 0.03 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $34.00 Million | $6.53 Billion | -$586.88 Million | 0.01x | N/A |
| 2017 | $71.94 Million | $6.97 Billion | -$391.34 Million | 0.01x | N/A |
| 2018 | $45.69 Million | $7.65 Billion | $219.76 Million | 0.01x | 0.21x |
| 2019 | $21.98 Million | $7.57 Billion | $289.46 Million | 0.00x | 0.08x |
| 2020 | $58.46 Million | $7.80 Billion | -$211.88 Million | 0.01x | N/A |
| 2021 | $63.81 Million | $8.91 Billion | -$31.47 Million | 0.01x | N/A |
| 2022 | $65.22 Million | $10.39 Billion | -$21.49 Million | 0.01x | N/A |
| 2023 | $97.24 Million | $12.07 Billion | $475.97 Million | 0.01x | 0.20x |
| 2024 | $101.96 Million | $12.81 Billion | $4.21 Billion | 0.01x | 0.02x |
| 2025 | $82.78 Million | $5.62 Billion | $2.50 Billion | 0.01x | 0.03x |
Competitor Companies of INDSWFTLAB by Market Capitalization
Companies near Ind-Swift Laboratories Limited in the global market cap rankings as of June 18, 2026.
Key companies related to Ind-Swift Laboratories Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #631 globally with a market cap of $43.86 Billion USD ( CN¥299.75 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #634 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.27 |
| #631 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.86 Billion | CN¥46.99 |
| #634 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Ind-Swift Laboratories Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Ind-Swift Laboratories Limited's market cap moved from $34.84 Million to $ 152.59 Million, with a yearly change of 15.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs152.59 Million | +84.32% |
| 2025 | Rs82.78 Million | -18.81% |
| 2024 | Rs101.96 Million | +4.85% |
| 2023 | Rs97.24 Million | +49.10% |
| 2022 | Rs65.22 Million | +2.21% |
| 2021 | Rs63.81 Million | +9.16% |
| 2020 | Rs58.46 Million | +166.03% |
| 2019 | Rs21.98 Million | -51.90% |
| 2018 | Rs45.69 Million | -36.49% |
| 2017 | Rs71.94 Million | +111.60% |
| 2016 | Rs34.00 Million | -2.43% |
| 2015 | Rs34.84 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Ind-Swift Laboratories Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $152.59 Million USD |
| MoneyControl | $152.59 Million USD |
| MarketWatch | $152.59 Million USD |
| marketcap.company | $152.59 Million USD |
| Reuters | $152.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more